Case report: Persistent hypogammaglobulinemia in thymoma-associated myasthenia gravis: the impact of rituximab or Good's syndrome?

IntroductionRituximab (RTX) showed good efficacy and safety for patients with myasthenia gravis. However, the percentage of peripheral CD20+ B cell may be absent for years after low dose of RTX treatment. Persistent hypogammaglobulinemia and opportunistic infection may occur in patients under treatm...

Descripción completa

Detalles Bibliográficos

Autores principales:	Jingru Ren, Jianchun Wang, Ran Liu, Jing Guo, Yan Yao, Jingjing Luo, Hongjun Hao, Feng Gao
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Frontiers Media S.A. 2023-05-01
Colección:	Frontiers in Neurology
Materias:	myasthenia gravis (MG) rituximab (RTX) hypogammaglobulinemia infections Good's syndrome (GS)
Acceso en línea:	https://www.frontiersin.org/articles/10.3389/fneur.2023.1152992/full
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!